HIV Therapeutic Compounds Resolving Viral Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV-1 infections face challenges with the emergence of drug-resistant HIV strains, necessitating the development of new antiretroviral agents.
Innovation Solution
A compound of Formula (I) and its pharmaceutically acceptable salts, which are designed to treat HIV infections, either alone or in combination with other therapeutic agents such as HIV protease inhibitors or reverse transcriptase inhibitors, are provided. The compound has a specific structural configuration that includes variously substituted rings and functional groups, allowing for potential efficacy against HIV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly active antiretroviral therapies (HAART) are used to treat HIV-1 infections, then viral load is reduced and disease progression is delayed, but HIV strains resistant to current therapies emerge
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antiretroviral compounds through various substituents (Z1, Z2, Z3, Z4 groups) and ring configurations (rings A and B) to create new compounds with altered properties that can effectively target resistant HIV strains while maintaining therapeutic efficacy
Solution Approach 2:
The patent employs composite materials by combining multiple structural elements (heteroaryl rings, carbocyclic rings, heterocyclic rings, and various functional groups) into complex molecular structures that provide both antiviral activity and resistance to viral mutations, creating a multi-faceted approach to combating HIV resistance
2Reliability
If new antiretroviral agents are developed to overcome resistance, then efficacy against resistant strains may improve, but treatment complexity and development time increase
Solution Approach 1:
The patent applies segmentation by dividing the complex antiretroviral compound into distinct modular components (ring A, ring B, and various substituent positions) that can be independently varied and optimized, allowing systematic development of new agents against resistant strains without requiring complete redesign of the entire molecular structure
Solution Approach 2:
The patent employs universality by designing a core molecular framework with multiple possible substituent configurations that can serve multiple therapeutic functions, potentially addressing different resistant strains with variations of the same base structure, thereby reducing overall treatment complexity
Data Source
AI summary
Compounds of Formula I, or salts thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, intermediates useful for preparing compounds of Formula I and therapeutic, methods for treating a Retroviridae viral infection, in particular infection caused by the HIV virus.